Home
News
Screeners
Insights
Chandra Bhagat Pharma
40.
00
0.00
(0.00%)
Market Cap
₹30.20 Cr
PE Ratio
9.90
Industry
Healthcare
Buy
Sell
Company Performance:
1D
0.00%
1M
0.00%
6M
0.00%
1Y
-2.68%
5Y
0.00%
View Company Insights
Latest news about Chandra Bhagat Pharma
BSE grants in-principle approval for Chandra Bhagat Pharma warrant issue
6 days ago
BSE grants in-principle approval for 66,00,000 convertible warrants. Warrants convertible into equity shares at minimum ₹44 per share. Issue targeted at promoters and non-promoters on preferential basis. Company must ensure allottees avoid intra-day trading before allotment.
Chandra Bhagat Pharma AGM resolutions pass unanimously with 100% support
Sep 03, 2026
Chandra Bhagat Pharma issues AGM notice corrigendum for warrant issue
Aug 20, 2026
Chandra Bhagat Pharma seeks approval for ₹29.04 cr warrant issue
Aug 06, 2026
Chandra Bhagat Pharma plans fund raise via preferential allotment
Jul 30, 2026
More news about Chandra Bhagat Pharma
25
May 26
Chandra Bhagat Pharma FY26 net profit rises 255% to ₹304.61 lakh
Chandra Bhagat Pharma Limited reported a 255% increase in net profit to ₹304.61 lakh for FY26, with revenue from operations rising 30.9% to ₹11,627.17 lakh. The board approved the audited financial results on May 25, 2026. Statutory Auditors M/S A Y & Company issued an unmodified opinion.
01
Apr 26
Chandra Bhagat Pharma Limited Opens New International Office in Dubai, UAE
Chandra Bhagat Pharma Limited has established a new international office in Dubai, UAE, as part of its strategic global expansion plans. The International Business/Representative Office, located in Sharjah Media City, commenced operations on March 31, 2026, with formation number 2645307. The initiative aims to expand the company's global footprint, enhance export opportunities, and strengthen international client relationships. The company has obtained proper regulatory approvals from Sharjah Media City Free Zone Authority and informed BSE Limited in compliance with SEBI listing requirements.
21
Jan 26
Chandra Bhagat Pharma Files Corporate Governance Non-Applicability Certificate for Q3 FY26
Chandra Bhagat Pharma Limited filed a certificate with BSE on January 21, 2026, stating corporate governance provisions are not applicable for Q3 FY26 ended December 31, 2025. The exemption is based on the company's SME Exchange listing under SEBI Regulation 15, which provides relief from multiple corporate governance requirements including Regulations 17-27 and specific clauses of Regulation 46 and Schedule V.
13
Nov 25
Chandra Bhagat Pharma Reports Half-Year Financial Results for September 2025
Chandra Bhagat Pharma Limited announced its unaudited financial results for the half year ended September 30, 2025. The company reported revenue from operations of ₹2,354.60 lakhs and a profit after tax of ₹44.91 lakhs. The results were approved by the Board of Directors and reviewed by A Y & Company, Chartered Accountants. The company's trading window will reopen 48 hours after the announcement of the financial statement, in compliance with SEBI regulations on insider trading.
Chandra Bhagat Pharma
40.
00
0.0
(0.0%)
1 Year Returns:
-2.68%
Industry Peers
Sun Pharmaceutical
1,743.00
(-
0.
90
%)
Divis Laboratories
9,087.00
(-
0.
63
%)
Torrent Pharmaceuticals
4,558.70
(+
0.
00
%)
Laurus Labs
2,069.00
(+
0.
43
%)
Zydus Life Science
1,113.90
(-
0.
81
%)
Cipla
1,324.10
(-
0.
08
%)
Dr Reddys Laboratories
1,242.50
(+
0.
77
%)
Aurobindo Pharma
1,621.40
(-
2.
73
%)
Mankind Pharma
2,253.20
(-
0.
98
%)
Lupin
1,939.20
(-
1.
14
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar